Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727078 | 1.00 | TLR4 (0.39) | TLR4ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL30721778 | 0.87 | ALDH1A1 (0.40) | TLR4ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL182497 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL1528558 | 0.84 | PSEN1 (0.38) | ALDH1A1KMT2APOLB | |
| SCHEMBL15416184 | 0.82 | MAPT (0.43) | TLR4ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL17338856 | 0.81 | TLR4 (0.33) | TLR4ALDH1A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL12555452 | 0.80 | ALDH1A1 (0.31) | ALDH1A1KMT2AMAPK1 | |
| SCHEMBL1860012 | 0.80 | ALDH1A1 (0.39) | TLR4ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL5111017 | 0.79 | TLR4 (0.43) | TLR4ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL25981634 | 0.79 | ALDH1A1 (0.40) | TLR4ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4384223-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040259914-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-23 | — | — | US | disclosed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
| US-5134143-A | Dopamine Agonists | ELI LILLY AND COMPANY (US) | 1992-07-28 | — | — | US | disclosed |
| US-4977160-A | DOPAMINE AGONISTS; PARKINSON*S DISEASE | ELI LILLY AND COMPANY (US) | 1990-12-11 | — | — | US | disclosed |
| US-4826986-A | DOPAMINE AGONISTS | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0250179-A2 | BCD tricyclic ergoline part-structure analogues | ELI LILLY AND COMPANY (US) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | TLR4 729/4885ALDH1A1 1095/4885MAPT 4610/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | TLR4 553/4885ALDH1A1 1039/4885MAPT 4636/4885 |
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | TLR4 764/4885ALDH1A1 4466/4885MAPT 4594/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | TLR4 1099/4885ALDH1A1 1627/4885MAPT 3842/4885 |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | TLR4 868/4885ALDH1A1 1022/4885MAPT 4652/4885 |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | HAVCR2, CD47, CYTH3 | TLR4 780/4885ALDH1A1 4788/4885MAPT 4231/4885 |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | TLR4 764/4885ALDH1A1 4466/4885MAPT 4594/4885 |
| US-20040259914-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCR1, CXCR1 | TLR4 436/4885ALDH1A1 671/4885MAPT 4728/4885 |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCR1, CCL11, CXCR1 | TLR4 901/4885ALDH1A1 948/4885MAPT 4712/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | TLR4 762/4885ALDH1A1 1402/4885MAPT 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.